ALMIRALL S.A. (ALM.MC)
Develops medicines and treatments for skin diseases like psoriasis and eczema.
11.68+0.00%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+14.1%
The outlook
Almirall trades at €11.68 with strong analyst backing—the consensus leans bullish with an average price target about 24% above current levels. The stock sits in the lower portion of its 52-week range and shows mixed momentum against its moving averages, reflecting a cautious near-term picture despite optimistic analyst sentiment.
What’s behind the score
Analyst consensusStrong Buy — 1.5 avg of 12 analysts
Price trendMixed vs its moving averages
52-week range41% of the way from its 52-week low to high
Price targetAvg target +24% vs current price
Analyst price target
~12-month · 12 analysts14.51average target+24.2% vs now
Now 11.68
Low 12.50High 17.50
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
—
52-wk high
13.98
52-wk low
10.06
50-day avg
11.23
200-day avg
12.21
Trailing P/E
41.7